Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris—
- 85 Downloads
Nitrates have long been used in the treatment of stable angina pectoris. We set out to show that trapidil, a triazolopyrimidine with a mode of action different from that of nitrates, is not inferior to isosorbidedinitrate (ISDN) in the treatment of this clinical syndrome.
Patients and Methods
We studied the efficacy of 200 mg trapidil (t.i.d.) vs. ISDN (20 mg b.i.d.) in patients with chronic stable angina treated for 12 weeks. The therapeutic effect was measured in terms of responder rate as change in total exercise time (TET) by at least 60 seconds using the bicycle ergometer test.
A total of 648 patients were included in the study. Responder rates in the Per– Protocol (PP) population (n = 529) were 50.4% (n = 133) in the trapidil group and 52.5% (n = 139) in the ISDN group (p = 0.233). As the lower non–inferiority limit (–15%) was clearly excluded from the 95% CI (pp: –10.6%, +6.4%; ITT –9.7%, 5.7%), non–inferiority of trapidil compared to ISDN can be concluded. Trapidil 200 mg t.i.d. combined with short–acting NTG prn as rescue medication over 12 weeks in subjects with chronic stable angina pectoris proved to have similar effects on TET and on other clinical endpoints as ISDN 20 mg b.i.d. The secondary efficacy analyses did not reveal any clinically relevant differences between treatment groups, and were not in conflict with the non–inferiority claim. Patients in the ISDN group had significantly more headach (34.1%; n = 110) compared to those taking trapidil (19.3%, n = 62; p <0.0001).
Overall results of this study show that both drugs are equally effective and safe for the short–term treatment of patients with chronic stable angina pectoris and that trapidil can be considered as therapeutically equivalent to ISDN.
Key wordsChronic angina pectoris trapidil ISDN
Unable to display preview. Download preview PDF.
- 2.ACC/AHA/ACP–ASIM (1999) Practice guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 33:2092–2197Google Scholar
- 7.Parker JO, Baird MG (1994) Efficacy of eccentric dosing with sustained–release isosorbide dinitrate in patients with angina pectoris. Can J Card 10:909–912Google Scholar
- 8.Caramori PR, Zago AJ (2000) Endothelial dysfunction and coronary artery disease. Arg Bras Cardiol 75:163–182Google Scholar
- 12.Sichelschmidt OJ, Hahnefeld C, Hohlfeld Th et al (2003) Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity. Cardiovascular Research (58):602–610Google Scholar
- 13.Schrör K, Zwaka P, Tannhäuser R (1998) Cardioprotective actions of Trapidil in myocardial ischemia involve inhibition of the activation of NfKb. Exp Biol, p 198Google Scholar
- 14.Boenisch D, Weber AA, Wittpoth M et al (1998) Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase. A Mol Pharmacol 54:241–248Google Scholar
- 15.Wittpoth M et al (1997) Trapidil inhibits PDGF–BB and LPS induced translocation of NFκB in vascular smooth muscle cells. Naunyn Schmied Arch Pharmacol 355/4 SupplGoogle Scholar
- 16.Schroer K, Bönisch D (1997) Trapidil inhibits RAF–1 kinase in vascular smooth muscle cells via activation of protein kinase A (PKA). Circulation 96:I–1–I–901Google Scholar
- 18.Aßmann I, Lehrl I, Lehrl S et al (1996) Behandlung der körperlichen, emotionalen und kognitiven Belastbarkeit bei Patienten mit koronarer Herzkrankheit unter Trapidil im Vergleich zu Nifedipin. Arzneimittelforschung 46/9:868–874Google Scholar
- 20.ESC (1993) Working Group on Exercise Physiology, Physiopathology and Electrocardiography. Guidelines for cardiac exercise testing. Eur Heart J 14:969–988Google Scholar
- 27.Walker JM, Curry PVL, Bailey AS et al (1996) A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Internat J Cardiol 53:117–126Google Scholar
- 30.Eteiba H, Hutton, I Foale RA et al (1991) Acute and chronic effects of once–daily isosorbide–5–mononitrate on exercise capacity of patients with angina pectoris treated with betablocking agent. Br J Clin Pharmacol 45:185–188Google Scholar
- 31.Davies GJ, Kobrin I, Caspi A et al (1997) Long–term anti–anginal and anti–ischemic effects of mibefradil, the novel T–type calcium channel blocker: A multicentre, double–blind, placebo–controlled, randomized comparison with sustained–release diltiazem. Am Heart J 134:220–228CrossRefPubMedGoogle Scholar
- 39.Schoebel FC, Peters AJ, Schannwell CM et al (1998) Detection of antiischemic therapeutic effectiveness in patients with refractory angina pectoris and end–stage coronary artery disease– Long–term intermittent urokinase therapy. Z Kardiol 87(Suppl 2):s188–s192Google Scholar
- 41.Gulba DC, Eichstädt H, Engberding R et al (2000) Empfehlungen des International Cardiology Forum (ICF) 1998 zur Revisison der bestehenden Richtlinien zur Diagnostik und Therapie der instabline Angina pectoris und des nicht–transmuralen Myokardinfarktes. Z Kardiol 89:706–721CrossRefPubMedGoogle Scholar